Company

Advanced Biodesign is driven by the ambition to treat all patients facing chemotherapy-resistant cancers with elevated levels of ALDH1.

Since its inception in 2010, this French biotechnology company has :

1/ confirmed the pivotal role of ALDH1 enzymes in the metabolism of cancer cells and immunomodulation.

2/ developed a pipeline of several ALDH1 inhibitors with the potential to be a game changer in the patient care.

3/ entered clinical trial in early 2023 with its lead ABD 3001 targeting acute myeloid leukemia (AML). Initial results suggest a good safety profile. The 2nd Lead ABD 0171 is developed in solid tumors and has a potentiated effect in combination with anti-PD1.

4/ developed a predictive and prognostic test called ALDESCREEN® to identify and stratify patients.

Science

ALDH FAMILY

Aldehyde Dehydrogenases (ALDHs) belong to a family of enzymes that play a key role in the metabolism of endogenous and exogenous aldehydes. This group of intracellular enzymes plays a pivotal role in embryogenesis and cell differentiation as well as in cancer progression by mediating retinoic acid signalling. Their functional activity also extends to cellular redox homeostasis via detoxification of reactive aldehydes derived from lipid peroxidation and other metabolic processes thus, playing a major cytoprotective role in cells.

MECHANISM OF ACTION

ABD-3001 A FIRST-IN-CLASS INHIBITOR

ABD-3001 is a suicidal inhibitor of ALDH1 and 3. It blocks the enzyme activity irreversibly causing rapid accumulation of reactive aldehydes in tumour cells, beyond critical threshold. The accumulated aldehydes, notably HNE and MDA form genotoxic adducts with protein and DNA affecting the oncogenic signalling pathways that participate in cell proliferation.

Our vision

Advanced Biodesign

Based on our expertise in cancer metabolism and know-how in specific cell death called “apoptosis”, we will develop a new way to treat cancer to overcome actual stratification of cancer to bring new hope for patient. By focusing on rare or bad-prognostic cancer, Advanced BioDesign offer innovative therapy to target markets with high unmet medical needs in cancer.

News

Advanced Biodesign, Winner of the France 2030 Plan's call for "I-Demo” Projects to Finance its "ODYSSEY" Clinical Trial With Up To €3M

Advanced BioDesign's winning project is its first-in-human clinical trial of its drug candidate ABD-3001 for patients with acute myeloid leukaemia (AML) who are resistant to standard treatments. As part of the France 2030 plan, the "i-Demo" scheme supports the development of highly innovative, high added-value products and services to strengthen France's scientific and technological capabilities.

Advanced BioDesign announces 14.3 million euros of additional funding from its main shareholder Xerys Invest

Two months after the start of "ODYSSEY”, the first-in-human clinical trial targeting acute myeloid leukaemia, Advanced BioDesign has signed an agreement with its historical shareholder, Xerys Invest, for a capital injection of 14.3 million euros.